Market Cap 544.22M
Revenue (ttm) 482.04M
Net Income (ttm) 860,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.18%
Debt to Equity Ratio 0.00
Volume 985,500
Avg Vol 813,238
Day's Range N/A - N/A
Shares Out 126.86M
Stochastic %K 33%
Beta 1.68
Analysts Strong Sell
Price Target $8.00

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 575 0775
Address:
85 Dan Road, Canton, United States
Mobagri
Mobagri Oct. 1 at 11:38 AM
$ORGO In 2026 they won’t have the 50M expense for the phase 3 trial, so income technically should be 50M more. Big difference
1 · Reply
highnihilism
highnihilism Oct. 1 at 11:35 AM
$CEPI Rex Crypto Equity Premium Income ETF Trades: 1 | Total $: 624 | 1.23 × 90-Day Avg $: 507 | Call $: 624 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $ORGO Organogenesis Holdings Trades: 4 | Total $: 625 | 0.15 × 90-Day Avg $: 4.3 K | Call $: 620 | Put $: 5 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $MCHB Mechanics Bancorp Trades: 1 | Total $: 620 | 0.50 × 90-Day Avg $: 1.2 K | Call $: 620 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $WEAV Weave Communications Trades: 6 | Total $: 677 | 0.20 × 90-Day Avg $: 3.4 K | Call $: 617 | Put $: 60 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
MaxProfitTrades
MaxProfitTrades Sep. 30 at 1:51 PM
$ORGO who caught the dip 😎
0 · Reply
josegodoy
josegodoy Sep. 30 at 1:00 PM
$ORGO recently a challenge of/towards the 200-day line have been a pretty bet for the bulls….5th times the charm?
1 · Reply
Cutz7
Cutz7 Sep. 26 at 9:48 PM
$ORGO there’s no way this gets on formulary anywhere. Insurances won’t cover anything without a statistically significant result. DOA
0 · Reply
Mobagri
Mobagri Sep. 26 at 3:42 PM
$ORGO • 🧾 AI analysis: 1. Consistency of direction • Trial 1: met primary endpoint (p=0.0177). • Trial 2: numerical benefit, narrowly missed prespecified alpha (p=0.0393 vs 0.023). • Both show directionally consistent benefit. 2. Pooled analysis • Pre-specified IPD pooled SAP: combined data statistically significant for pain reduction. • Clinically meaningful effect size: ≥0.5 WOMAC units → exceeds MCID thresholds. 3. Responder rates • ≥30% and ≥50% pain reduction responder rates: strong separation vs saline, • significant improvement in function (Trial 2 function endpoint p<0.0001). • safe: no RPOA, no accelerated structural damage, no new safety signals. • Favorable compared to corticosteroids, HA injections, and prior NGF inhibitors. • RMAT designation demonstrates FDA recognition of unmet need • Willing to accept narrower initial label (e.g., severe OA KL3–4) if that eases approval. • Commitment to post-marketing confirmatory trial to strengthen long-term data.
0 · Reply
Linda11S
Linda11S Sep. 26 at 3:09 PM
$ORGO 🤔
1 · Reply
Mobagri
Mobagri Sep. 26 at 1:39 PM
$ORGO The best thing they have going is the safety profile. When the FDA feels a drug is safe and do no harm, then they feel more comfortable giving conditional approval pending confirmatory trial. That’s my opinion.
2 · Reply
Mobagri
Mobagri Sep. 26 at 12:07 PM
$ORGO they should switch the primary endpoint to maintenance of functionality which was statistically very different. Group with Renu kept their knee function. If I were a patient that would be more important than mere pain cause I can pop a Tylenol for that but no treatment including injection in joints has maintained function as far as I know.
0 · Reply
notreload_ai
notreload_ai Sep. 26 at 11:57 AM
$ORGO ReNu's second trial for knee pain (OA) missed its main goal, but still showed numerical improvement and function benefits. Organogenesis, confident in the data from all three large studies (1,300+ patients), will ask the FDA to review combined results for approval. https://notreload.xyz/organogenesis-trial-failure-sinks-stock-price/
0 · Reply
Latest News on ORGO
Why Is Organogenesis Stock Trading Lower Friday?

Sep 26, 2025, 11:24 AM EDT - 8 days ago

Why Is Organogenesis Stock Trading Lower Friday?


Organogenesis Provides Update on Second Phase 3 ReNu® Study

Sep 25, 2025, 4:50 PM EDT - 9 days ago

Organogenesis Provides Update on Second Phase 3 ReNu® Study


Organogenesis Commends Final LCDs

Nov 15, 2024, 9:25 AM EST - 11 months ago

Organogenesis Commends Final LCDs


Organogenesis Shares ReNu® Program Update

Aug 8, 2024, 4:04 PM EDT - 1 year ago

Organogenesis Shares ReNu® Program Update


Mobagri
Mobagri Oct. 1 at 11:38 AM
$ORGO In 2026 they won’t have the 50M expense for the phase 3 trial, so income technically should be 50M more. Big difference
1 · Reply
highnihilism
highnihilism Oct. 1 at 11:35 AM
$CEPI Rex Crypto Equity Premium Income ETF Trades: 1 | Total $: 624 | 1.23 × 90-Day Avg $: 507 | Call $: 624 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $ORGO Organogenesis Holdings Trades: 4 | Total $: 625 | 0.15 × 90-Day Avg $: 4.3 K | Call $: 620 | Put $: 5 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $MCHB Mechanics Bancorp Trades: 1 | Total $: 620 | 0.50 × 90-Day Avg $: 1.2 K | Call $: 620 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $WEAV Weave Communications Trades: 6 | Total $: 677 | 0.20 × 90-Day Avg $: 3.4 K | Call $: 617 | Put $: 60 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
MaxProfitTrades
MaxProfitTrades Sep. 30 at 1:51 PM
$ORGO who caught the dip 😎
0 · Reply
josegodoy
josegodoy Sep. 30 at 1:00 PM
$ORGO recently a challenge of/towards the 200-day line have been a pretty bet for the bulls….5th times the charm?
1 · Reply
Cutz7
Cutz7 Sep. 26 at 9:48 PM
$ORGO there’s no way this gets on formulary anywhere. Insurances won’t cover anything without a statistically significant result. DOA
0 · Reply
Mobagri
Mobagri Sep. 26 at 3:42 PM
$ORGO • 🧾 AI analysis: 1. Consistency of direction • Trial 1: met primary endpoint (p=0.0177). • Trial 2: numerical benefit, narrowly missed prespecified alpha (p=0.0393 vs 0.023). • Both show directionally consistent benefit. 2. Pooled analysis • Pre-specified IPD pooled SAP: combined data statistically significant for pain reduction. • Clinically meaningful effect size: ≥0.5 WOMAC units → exceeds MCID thresholds. 3. Responder rates • ≥30% and ≥50% pain reduction responder rates: strong separation vs saline, • significant improvement in function (Trial 2 function endpoint p<0.0001). • safe: no RPOA, no accelerated structural damage, no new safety signals. • Favorable compared to corticosteroids, HA injections, and prior NGF inhibitors. • RMAT designation demonstrates FDA recognition of unmet need • Willing to accept narrower initial label (e.g., severe OA KL3–4) if that eases approval. • Commitment to post-marketing confirmatory trial to strengthen long-term data.
0 · Reply
Linda11S
Linda11S Sep. 26 at 3:09 PM
$ORGO 🤔
1 · Reply
Mobagri
Mobagri Sep. 26 at 1:39 PM
$ORGO The best thing they have going is the safety profile. When the FDA feels a drug is safe and do no harm, then they feel more comfortable giving conditional approval pending confirmatory trial. That’s my opinion.
2 · Reply
Mobagri
Mobagri Sep. 26 at 12:07 PM
$ORGO they should switch the primary endpoint to maintenance of functionality which was statistically very different. Group with Renu kept their knee function. If I were a patient that would be more important than mere pain cause I can pop a Tylenol for that but no treatment including injection in joints has maintained function as far as I know.
0 · Reply
notreload_ai
notreload_ai Sep. 26 at 11:57 AM
$ORGO ReNu's second trial for knee pain (OA) missed its main goal, but still showed numerical improvement and function benefits. Organogenesis, confident in the data from all three large studies (1,300+ patients), will ask the FDA to review combined results for approval. https://notreload.xyz/organogenesis-trial-failure-sinks-stock-price/
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 10:11 AM
BTIG updates rating for Organogenesis Holdings ( $ORGO ) to Buy, target set at 7.
0 · Reply
Mobagri
Mobagri Sep. 25 at 10:54 PM
$ORGO one option for the FDA is to approve Renu because it was extremely safe but with the label “clinical trials provided mixed results for pain reduction”. At least it gets approved and then the company needs to run a confirmatory trial for pain reduction.
0 · Reply
whatabigcockyouhave
whatabigcockyouhave Sep. 25 at 8:53 PM
$ORGO so let me get this straight….. data is amazing…. the want to submit for FDA approval, and it drops like a rock?
1 · Reply
josegodoy
josegodoy Sep. 24 at 3:43 PM
$ORGO rooting for her
0 · Reply
AnonMav
AnonMav Sep. 24 at 3:27 PM
0 · Reply
Mobagri
Mobagri Sep. 22 at 10:47 PM
$ORGO Tea is brewing
1 · Reply
microdude
microdude Sep. 22 at 9:16 PM
$ORGO lot of volume today, 1.7mil, for this usually thin stock
1 · Reply
josegodoy
josegodoy Sep. 20 at 6:46 PM
$ORGO my guess is she could see $4.00 to $4.20 - at $4.47-ish bulls MIGHT mount a defense - data readout due: “September 2025”, this could be epic - read an article awhile ago about how the data was treated in the first osteo trial (the author didn’t agree with the treatment of the data and argued that, the trial would’ve failed if not for the way the data was treated)….whatever - they products and those sales should eventually support the share price This is a risky bet. I have composition but I’m watching her.
1 · Reply
Mobagri
Mobagri Sep. 18 at 6:04 PM
$ORGO when are they publishing the data? Supposed to in September The CEO is old and slow.
1 · Reply
josegodoy
josegodoy Sep. 18 at 8:40 AM
$ORGO the market is demanding a margin of safety…where that price point is, is anyone’s guess
0 · Reply
Mobagri
Mobagri Sep. 17 at 4:37 PM
$ORGO probably last week you can buy in the 4s.
0 · Reply
biotechshrek
biotechshrek Sep. 17 at 2:02 PM
$ORGO if data is good, as it should be, this is going to squeeze like crazy. Look at the 13D’s… north of 85% of float is locked up with approx 10m shares short. Good data and they are TOAST! 🔥 back in Feb this name trade 58m shares in a day… this time around could be 100m with the shorts rushing for the door. Set limits high! (This is not financial advice)
2 · Reply